Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

110 projects found matching your search criteria :

  1. Simultaneous stimulation of muscarinic M4 receptor and selected receptors involved in the regulation of glutamate releas...

    Call: OPUS 9 , Panel: NZ7

    Principal investigator: dr hab. Joanna Wierońska

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  2. Targeted inhibition of STATs and IRFs as a novel treatment strategy in cardiovascular disease

    Call: OPUS 9 , Panel: NZ2

    Principal investigator: prof. Johannes Bluijssen (Bluyssen)

    Uniwersytet im. Adama Mickiewicza w Poznaniu, Wydział Biologii

  3. Next generation in vitro experimental model of melanoma for pharmacological studies

    Call: OPUS 8 , Panel: NZ7

    Principal investigator: prof. Małgorzata Czyż

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  4. Efficacy, toxicity and immunogenicity of carriers made of bioengineered spider silk for targeted drug delivery

    Call: OPUS 8 , Panel: NZ7

    Principal investigator: dr hab. Hanna Dams-Kozłowska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Medyczny

  5. Identification of new, clinically relevant genetic and epigenetic aberrations by next-generation sequencing in chronic m...

    Call: HARMONIA 6 , Panel: NZ5

    Principal investigator: dr Tomasz Stokłosa

    Warszawski Uniwersytet Medyczny, Wydział Lekarski

  6. Identification of proline metabolic pathway as a molecular target for experimental regulation of apoptosis/autophagy in ...

    Call: OPUS 7 , Panel: NZ7

    Principal investigator: prof. Jerzy Pałka

    Uniwersytet Medyczny w Białymstoku, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej

  7. Research on human eosinophils as a potential therapeutic target.

    Call: PRELUDIUM 7 , Panel: NZ7

    Principal investigator: Marek Grosicki

    Uniwersytet Jagielloński - Collegium Medicum, Collegium Medicum, Wydział Farmaceutyczny

  8. Characteristics of neuropilin-1 (NRP1) as a target of antiangiogenic activity of immunomodulatory drugs in multiple myel...

    Call: OPUS 7 , Panel: NZ6

    Principal investigator: prof. Krzysztof Giannopoulos

    Uniwersytet Medyczny w Lublinie, II Wydział Lekarski z Oddziałem Anglojęzycznym

  9. Physicochemical characterization of cyclodextrins tailored for pH-dependent targeted therapy with anthracycline drugs

    Call: OPUS 7 , Panel: ST5

    Principal investigator: prof. Renata Bilewicz

    Uniwersytet Warszawski, Wydział Chemii

  10. New drug carriers in targeted anticancer therapy

    Call: OPUS 1 , Panel: ST5

    Principal investigator: prof. Artur Terzyk

    Uniwersytet Mikołaja Kopernika, Wydział Chemii

  11. GPR18 orphan receptor. Search for the tools to investigate GPR18 as potential therapeutic target

    Call: OPUS 6 , Panel: NZ7

    Principal investigator: prof. Katarzyna Kieć-Kononowicz

    Uniwersytet Jagielloński - Collegium Medicum, Collegium Medicum, Wydział Farmaceutyczny

  12. Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

    Call: OPUS 6 , Panel: NZ7

    Principal investigator: dr hab. Sylwia Flis

    Narodowy Instytut Leków

  13. Cross-talk between PXR and AR receptors in hormone-dependent cancers.

    Call: SONATA 5 , Panel: NZ7

    Principal investigator: dr Magdalena Niemira

    Politechnika Gdańska, Wydział Chemiczny

  14. Characteristics of the cell wall hydrolases of pathogenic bacteria Listeria monocytogenes and their partcipation in the ...

    Call: OPUS 5 , Panel: NZ6

    Principal investigator: dr hab. Magdalena Popowska

    Uniwersytet Warszawski, Wydział Biologii

  15. Transcription factor MeCP2 as an intracellular object of study on the mechanism of depression and as a potential pharmac...

    Call: SONATA 5 , Panel: NZ7

    Principal investigator: dr Magdalena Sowa-Kućma

    Instytut Farmakologii PAN

  16. Mitochondrial aldehyde dehydrogenase (ALDH2) as a new target for anti-atherosclerotic drugs

    Call: PRELUDIUM 1 , Panel: NZ4

    Principal investigator: Aneta Stachowicz

    Uniwersytet Jagielloński - Collegium Medicum, Collegium Medicum, Wydział Lekarski

  17. Preparation and physico-chemical evaluation of mesoporous oxide matrices as carriers in a model of the implant to the bo...

    Call: OPUS 4 , Panel: NZ7

    Principal investigator: prof. Wiesław Sawicki

    Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej

  18. Evaluation of peroxiredoxins 1 and 2 along with the thioredoxin-thioredoxin reductase system as new therapeutic targets ...

    Call: OPUS 4 , Panel: NZ7

    Principal investigator: dr hab. Radosław Zagożdżon

    Warszawski Uniwersytet Medyczny, I Wydział Lekarski

  19. DNA double-stranded break repair proteins as a target for personalized cancer therapy based on synthetic lethality

    Call: OPUS 4 , Panel: NZ7

    Principal investigator: dr hab. Tomasz Śliwiński

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  20. PHARMACOTHERAPY OF OSTEOARTHRITIS: TRPV1 AND CB1 RECEPTORS AND THEIR ENDOGENOUS LIGANDS AS NEW TARGETS FOR PHARMACOLOGIC...

    Call: SONATA BIS 2 , Panel: NZ7

    Principal investigator: dr hab. Katarzyna Starowicz-Bubak

    Instytut Farmakologii PAN

  21. The group III metabotropic glutamate receptors as a target for future antypsychotic drugs

    Call: MAESTRO 3 , Panel: NZ7

    Principal investigator: prof. Andrzej Pilc

    Instytut Farmakologii PAN

  22. The study of the role of mGluR8 in cancer cells - a potential target for new antitumor strategies

    Call: OPUS 3 , Panel: NZ3

    Principal investigator: dr Danuta Jantas

    Instytut Farmakologii PAN

  23. Multitasking polymeric lattices included selected DNA oligonucleotide sequences - synthesis, modifications and physioche...

    Call: SONATA 3 , Panel: ST5

    Principal investigator: dr Ewelina Zabost

    Uniwersytet Warszawski, Wydział Chemii

  24. Stimuli-responsive anion transporters for targeted drug delivery

    Call: OPUS 26 , Panel: ST5

    Principal investigator: dr hab. Michał Chmielewski

    Uniwersytet Warszawski, Centrum Nauk Biologiczno-Chemicznych

  25. Integrated multi-omics approach to accelerate anticancer drug discovery by targeting metabolic reprogramming in human co...

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr hab. Danuta Dudzik

    Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny

  26. PROteolysis TArgeting Chimeras (PROTACs) intended to knock down excessive amyloidogenic proteins, human islet amyloid po...

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr hab. Elżbieta Jankowska

    Uniwersytet Gdański, Wydział Chemii

  27. Deciphering the Chemoproteomics and Chemotranscriptomics of Anti-Alzheimer Drugs for Novel Druggable Target Identificati...

    Call: JPND Call 2023 , Panel: NZ5

    Principal investigator: prof. Krzysztof Sobczak

    Uniwersytet im. Adama Mickiewicza w Poznaniu

  28. Directed screening and evaluation of novel bactericidal compounds active againsttubercle bacilli and Mycobacterium absce...

    Call: OPUS 25 , Panel: NZ7

    Principal investigator: prof. Jarosław Dziadek

    Instytut Biologii Medycznej Polskiej Akademii Nauk

  29. Curdlan-based biomaterial as a nanostructure carrier for controlled and targeted drug delivery in the treatment of deep ...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Aleksandra Nurzyńska

    Uniwersytet Medyczny w Lublinie

  30. Cuproptosis, a novel pathway of regulated cell death as a therapeutic target in treatment-naïve and targeted therapy-res...

    Call: OPUS 25 , Panel: NZ5

    Principal investigator: dr hab. Mariusz Hartman

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  31. Targeting Energy Metabolism for Precision Cancer Therapy: Novel Inhibitors of LDH-A and PDK1 as Potential Strategies to ...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Marika Frańczak

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  32. Understanding the influence of structure and functionalisation of nanocarriers for targeted drug delivery on cell-nanost...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Karolina Krajewska

    Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

  33. The Role of the Mitochondrial Unfolded Protein Response (UPRmt) in Endothelial Function: a Possible Novel Target for the...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Sylwester Mosiołek

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  34. Conjugates of peptide nucleic acids with aminoglycosides and fluoroquinolones as a novel strategy to target multi-drug r...

    Call: PRELUDIUM 22 , Panel: ST5

    Principal investigator: Izabela Siekierska

    Uniwersytet Warszawski, Centrum Nowych Technologii Uniwersytetu Warszawskiego

  35. Senolytic nanoplatform to target and eliminate skin cancer Zombie cells

    Call: M-ERA.NET 3 Call 2022 , Panel: ST5

    Principal investigator: dr hab. Anna Lewińska

    Uniwersytet Rzeszowski

  36. Targeted inhibition of hypusination pathway

    Call: OPUS 24 , Panel: NZ7

    Principal investigator: dr Przemysław Grudnik

    Uniwersytet Jagielloński, Małopolskie Centrum Biotechnologii Uniwersytetu Jagiellońskiego

  37. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p...

    Call: PRELUDIUM BIS 4 , Panel: NZ7

    Principal investigator: prof. Tomasz Gośliński

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  38. Research on the preparation of new, hydrogel nanosystems for targeted therapy of colorectal cancer

    Call: SONATA 18 , Panel: NZ7

    Principal investigator: dr Urszula Piotrowska

    Warszawski Uniwersytet Medyczny

  39. Customized DNA-based nanocarriers to boost heart healing

    Call: M-ERA.NET 3 Call 2022 , Panel: NZ7

    Principal investigator: dr Monika Bzowska

    Uniwersytet Jagielloński

  40. Gaining control on XBP1s signaling as a starting point for novel cancer therapies

    Call: OPUS 24 , Panel: NZ7

    Principal investigator: prof. Rafał Bartoszewski

    Uniwersytet Wrocławski, Wydział Biotechnologii

  41. Targeted drug delivery systems - synthesis and functionalization of nanocarriers

    Call: SONATA 2 , Panel: ST5

    Principal investigator: dr Krzysztof Szczepanowicz

    Instytut Katalizy i Fizykochemii Powierzchni im. Jerzego Habera PAN

  42. A double whammy for the NF-κB signalling pathway: development of TAK1 and IKKβ degraders against inflammation-driven dis...

    Call: OPUS 24 (LAP) , Panel: NZ7

    Principal investigator: dr hab. Anna Więckowska

    Uniwersytet Jagielloński, Collegium Medicum

  43. Brain-targeted β‐hydroxy-β‐methylbutyrate administration in the prevention of insulin resistance development in the hypo...

    Call: SONATA 18 , Panel: NZ7

    Principal investigator: dr Elżbieta Supruniuk

    Uniwersytet Medyczny w Białymstoku

  44. Computational deciphering of pro-ferroptotic cell death protein machinery as a fundamental step in the search for therap...

    Call: SONATA BIS 12 , Panel: ST4

    Principal investigator: dr Karolina Mikulska-Rumińska

    Uniwersytet Mikołaja Kopernika w Toruniu, Wydział Fizyki, Astronomii i Informatyki Stosowanej

  45. A smart stride for cancer: synergistic effect of co-delivery chemo- andphototherapeutic agents using magneto-fluorescent...

    Call: POLONEZ BIS 2 , Panel: NZ7

    Principal investigator: dr Prachi Ghoderao

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  46. Studies on the post-receptor mechanisms of TSPO in search of a novel therapeutic target of metabolic syndrome

    Call: PRELUDIUM 21 , Panel: NZ7

    Principal investigator: Łukasz Kurach

    Uniwersytet Medyczny w Lublinie

  47. Brain cytochrome P450 as a new target for the treatment of neurological and psychiatric diseases. Studies with human neu...

    Call: OPUS 23 , Panel: NZ7

    Principal investigator: prof. Władysława Daniel

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  48. The role of simultaneous and individual modulation of μ-opioid, sigma-1 and histamine H3 receptors as a new therapeutic ...

    Call: OPUS 23 , Panel: NZ7

    Principal investigator: dr Katarzyna Szczepańska

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  49. Impact of the CDK4/6 targeted degradation by PROTACs on immune checkpoint signaling in cancer

    Call: OPUS 22 , Panel: NZ7

    Principal investigator: dr Katarzyna Magiera-Mularz

    Uniwersytet Jagielloński, Wydział Chemii

  50. Novel broad-spectrum central nervous system active substances: optimization of their multi-target profile

    Call: OPUS 22 , Panel: NZ7

    Principal investigator: dr hab. Agnieszka Kaczor

    Uniwersytet Medyczny w Lublinie, Wydział Farmaceutyczny

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy